TORONTO, CANADA–(Marketwired – Aug. 5, 2015) – Arch Biopartners Inc (Arch) or (the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) announced today the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 9,095,541 titled, “Brain Tumor Targeting Peptides”, further protecting MetaMx™, the Company’s peptide based technology which targets brain tumour initiating cells (BTICs) and invasive glioma cells (IGCs).
Arch management anticipates that similar patents will be issued, in due course, in various major national markets that are members of the Patent Cooperation Treaty.
This U.S. patent issued today is the second related to MetaMx. In September 2013, the USPTO issued Patent 8,530,429 bearing the same name. Both patents are based on technology invented by Dr. Stephen Robbins, Dr. Donna Senger and Dr. Jennifer Rahn at the University of Calgary who previously assigned the patents to Arch.
“We are quite pleased to see another patent get issued for MetaMx while we continue to work toward the first human trial to target and image BTICs and IGCs in patients with malignant gliomas,” said Richard Muruve, CEO of Arch.
About Arch Biopartners
Arch Biopartners is a portfolio based biotechnology company established to develop new products and technology for unmet medical needs. The Company’s portfolio includes MetaMx, which targets brain tumor initiating cells; ABP569, a new treatment for respiratory Pseudomonas aeruginosa infections; and, Metablok, a potential treatment for sepsis and cancer metastasis.
Arch has also been developing its peptide-solid surface interface with the objective of reducing corrosion, biofilm formation and improving biocompatibility of various metals and plastics.
For more information on the Company, please consult the other public documents filed on SEDAR at www.sedar.com.
The Company has 53,189,679 common shares outstanding.
All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.